BDNF mimetics: GSB, GBK & GTSМиметики BDNF
What is it?
Small experimental mimetics of different BDNF loops, grouped for comparison of chemistry, signaling and behavioral results.
Research context
Small experimental mimetics of different BDNF loops, grouped for comparison of chemistry, signaling and behavioral results.
What the studies found
animal · 2023
Rat pharmacokinetics; plasma and brain LC-MS/MS
After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.
Limit: Preclinical findings do not establish human benefit or safety.
LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats. ↗animal · 2022
Rodent forced-swim tests; comparison with cell-signaling results
GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.
Limit: Behavioral proxies are not a clinical diagnosis or treatment outcome.
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human treatment trial assessed for this family
- Study methods
- —Member-specific studies; patents and archival leads identified separately
- Independent replication
- —Independent replication not established by the records collected here
- Source access
- —Primary abstracts, selected full texts, patents and explicit retrieval targets
- Safety evidence
- —Cell and animal effects do not establish human safety; analogues may differ
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Inside this research family
Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.
| Member | Identity | What the source supports |
|---|---|---|
| GSB-106 | Loop 4 dimer | Acute antidepressant-like activity in a rodent comparison; not a clinical antidepressant finding. |
| GSB-214 | Loop 1 dimer | Behavioral effects appeared with repeated administration in the comparison; not equivalent to GSB-106. |
| GTS-201 | Loop 2 dimer | Negative forced-swim result alongside separate rat brain-exposure measurements. |
| GSB-104 / GSB-120 / GBK-108 | Loop 4 patent examples | Sparse or conflicting assay descriptions; no shared clinical effect inferred. Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 ↗ |
| GSB-207 / GBK-201 | Loop 1 patent examples | Chemistry documented; member-specific evidence review incomplete. Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 ↗ |
Interpretation and open questions
GSB-104 is described with both unfavorable and favorable survival results in patent prose; assay conditions and original tables need reconciliation.
Trk phosphorylation or dependence does not by itself demonstrate direct binding to the receptor.
Linked sources
Explore the research map and unresolved leads ↗
LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats.
Markin PA, Moskaleva NE, Lebedeva SA, Kozin SV, Grigorevskikh EM, Kolik LG, Gudasheva TA, Appolonova SA · Journal of pharmaceutical and biomedical analysis
After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.
- Population / setting
- Rat pharmacokinetics; plasma and brain LC-MS/MS
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2
· Primary source linked above
The patent enumerates NGF and BDNF analogue series. GK-1 interfered with GK-2 protection in a cell experiment. GSB-104 has conflicting survival descriptions, and GK-2f appears without clear structure mapping.
- Population / setting
- Patent chemistry and preclinical examples
- What was checked
- Selected original-source text checked; full methodological review pending.
Limitations & review scope
- Patent proposals are not established clinical uses.
- Resolve code/structure ambiguities and assay-specific contradictions before interpreting activity.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk
· Primary source linked above
GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.
- Population / setting
- Rodent forced-swim tests; comparison with cell-signaling results
- What was checked
- Selected original-source text checked; full methodological review pending.
Limitations & review scope
- Behavioral proxies are not a clinical diagnosis or treatment outcome.
- Different schedules and models limit cross-compound comparisons.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.